Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Randomized, Open Labeled, Phase IV, Multicenter Study for Peginterferon Alfa-2a and Weight-based Ribavirin for 16 or 24 Weeks in genotype2 Chronic Hepatitis C Patients Who Achieved Rapid Virologic Response

NCT01056172 is registered in ClinicalTrials.gov with Pusan National University Yangsan Hospital as lead sponsor.

NCT NCT01056172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01056172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Randomized, Open Labeled, Phase IV, Multicenter Study for Peginterferon Alfa-2a and Weight-based Ribavirin for 16 or 24 Weeks in genotype2 Chronic Hepatitis C Patients Who Achieved Rapid Virologic Response
Lead sponsor
Pusan National University Yangsan Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
January 31, 2010
Completion date
December 31, 2012
Enrollment
164 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c